PUBLIC COMPANY
saveAjax Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Lilly confident in slow and steady Foundayo launch, as ex-US sales shineFoundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.biospace · 9d ago
- Lilly scores early positive data for new JAK drugAcquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.biopharma_dive · 2mo ago
- Lilly to buy startup Ajax in bid for a better JAK drugWorth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.biopharma_dive · 3mo ago
- STAT+: Astellas retries XLMTM gene therapy after deathsVeradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech newsstat · 3mo ago
comments(0)
5-min edit window · permanent after that